EGF Receptor Mabs and Chemotherapy in Breast Cancer.
Abstract
To establish a safety profile in patients with Stage IV, EGFr positive breast cancer, for which no curative standard exists, of C225 over a range of dose levels and to pharmacologically optimize the dosing regimen of loading and maintenance infusions administered during combination chemotherapy with weekly doses of paclitaxel.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 1996
- Accession Number
- ADA328029
Entities
People
- Andrew Seidman
- Larry Norton
Organizations
- Memorial Sloan Kettering Cancer Center